000143857 001__ 143857
000143857 005__ 20240229112610.0
000143857 0247_ $$2doi$$a10.1016/S1470-2045(19)30277-3
000143857 0247_ $$2pmid$$apmid:31151904
000143857 0247_ $$2ISSN$$a1470-2045
000143857 0247_ $$2ISSN$$a1474-5488
000143857 0247_ $$2altmetric$$aaltmetric:61217207
000143857 037__ $$aDKFZ-2019-01419
000143857 041__ $$aeng
000143857 082__ $$a610
000143857 1001_ $$aFangusaro, Jason$$b0
000143857 245__ $$aSelumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
000143857 260__ $$aLondon$$bThe Lancet Publ. Group$$c2019
000143857 3367_ $$2DRIVER$$aarticle
000143857 3367_ $$2DataCite$$aOutput Types/Journal article
000143857 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1565008433_4683
000143857 3367_ $$2BibTeX$$aARTICLE
000143857 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143857 3367_ $$00$$2EndNote$$aJournal Article
000143857 520__ $$aPaediatric low-grade glioma is the most common CNS tumour of childhood. Although overall survival is good, disease often recurs. No single universally accepted treatment exists for these patients; however, standard cytotoxic chemotherapies are generally used. We aimed to assess the activity of selumetinib, a MEK1/2 inhibitor, in these patients.The Pediatric Brain Tumor Consortium performed a multicentre, phase 2 study in patients with paediatric low-grade glioma in 11 hospitals in the USA. Patients aged 3-21 years with a Lansky or Karnofsky performance score greater than 60 and the presence of recurrent, refractory, or progressive paediatric low-grade glioma after at least one standard therapy were eligible for inclusion. Patients were assigned to six unique strata according to histology, tumour location, NF1 status, and BRAF aberration status; herein, we report the results of strata 1 and 3. Stratum 1 comprised patients with WHO grade I pilocytic astrocytoma harbouring either one of the two most common BRAF aberrations (KIAA1549-BRAF fusion or the BRAFV600E [Val600Glu] mutation). Stratum 3 comprised patients with any neurofibromatosis type 1 (NF1)-associated paediatric low-grade glioma (WHO grades I and II). Selumetinib was provided as capsules given orally at the recommended phase 2 dose of 25 mg/m2 twice daily in 28-day courses for up to 26 courses. The primary endpoint was the proportion of patients with a stratum-specific objective response (partial response or complete response), as assessed by the local site and sustained for at least 8 weeks. All responses were reviewed centrally. All eligible patients who initiated treatment were evaluable for the activity and toxicity analyses. Although the trial is ongoing in other strata, enrolment and planned follow-up is complete for strata 1 and 3. This trial is registered with ClinicalTrials.gov, number NCT01089101.Between July 25, 2013, and June 12, 2015, 25 eligible and evaluable patients were accrued to stratum 1, and between Aug 28, 2013, and June 25, 2015, 25 eligible and evaluable patients were accrued to stratum 3. In stratum 1, nine (36% [95% CI 18-57]) of 25 patients achieved a sustained partial response. The median follow-up for the 11 patients who had not had a progression event by Aug 9, 2018, was 36·40 months (IQR 21·72-45·59). In stratum 3, ten (40% [21-61]) of 25 patients achieved a sustained partial response; median follow-up was 48·60 months (IQR 39·14-51·31) for the 17 patients without a progression event by Aug 9, 2018. The most frequent grade 3 or worse adverse events were elevated creatine phosphokinase (five [10%]) and maculopapular rash (five [10%]). No treatment-realted deaths were reported.Selumetinib is active in recurrent, refractory, or progressive pilocytic astrocytoma harbouring common BRAF aberrations and NF1-associated paediatric low-grade glioma. These results show that selumetinib could be an alternative to standard chemotherapy for these subgroups of patients, and have directly led to the development of two Children's Oncology Group phase 3 studies comparing standard chemotherapy to selumetinib in patients with newly diagnosed paediatric low-grade glioma both with and without NF1.National Cancer Institute Cancer Therapy Evaluation Program, the American Lebanese Syrian Associated Charities, and AstraZeneca.
000143857 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000143857 588__ $$aDataset connected to CrossRef, PubMed,
000143857 7001_ $$aOnar-Thomas, Arzu$$b1
000143857 7001_ $$aYoung Poussaint, Tina$$b2
000143857 7001_ $$aWu, Shengjie$$b3
000143857 7001_ $$aLigon, Azra H$$b4
000143857 7001_ $$aLindeman, Neal$$b5
000143857 7001_ $$aBanerjee, Anuradha$$b6
000143857 7001_ $$aPacker, Roger J$$b7
000143857 7001_ $$aKilburn, Lindsay B$$b8
000143857 7001_ $$aGoldman, Stewart$$b9
000143857 7001_ $$aPollack, Ian F$$b10
000143857 7001_ $$aQaddoumi, Ibrahim$$b11
000143857 7001_ $$aJakacki, Regina I$$b12
000143857 7001_ $$aFisher, Paul G$$b13
000143857 7001_ $$aDhall, Girish$$b14
000143857 7001_ $$aBaxter, Patricia$$b15
000143857 7001_ $$aKreissman, Susan G$$b16
000143857 7001_ $$aStewart, Clinton F$$b17
000143857 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David T W$$b18$$udkfz
000143857 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b19$$udkfz
000143857 7001_ $$aVezina, Gilbert$$b20
000143857 7001_ $$aStern, Jessica S$$b21
000143857 7001_ $$aPanigrahy, Ashok$$b22
000143857 7001_ $$aPatay, Zoltan$$b23
000143857 7001_ $$aTamrazi, Benita$$b24
000143857 7001_ $$aJones, Jeremy Y$$b25
000143857 7001_ $$aHaque, Sofia S$$b26
000143857 7001_ $$aEnterline, David S$$b27
000143857 7001_ $$aCha, Soonmee$$b28
000143857 7001_ $$aFisher, Michael J$$b29
000143857 7001_ $$aDoyle, Laurence Austin$$b30
000143857 7001_ $$aSmith, Malcolm$$b31
000143857 7001_ $$aDunkel, Ira J$$b32
000143857 7001_ $$aFouladi, Maryam$$b33
000143857 773__ $$0PERI:(DE-600)2035574-9$$a10.1016/S1470-2045(19)30277-3$$gp. S1470204519302773$$n7$$p1011-1022$$tThe lancet <London> / Oncology Oncology$$v20$$x1470-2045$$y2019
000143857 909CO $$ooai:inrepo02.dkfz.de:143857$$pVDB
000143857 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000143857 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000143857 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000143857 9141_ $$y2019
000143857 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143857 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143857 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143857 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET ONCOL : 2017
000143857 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000143857 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000143857 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143857 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143857 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143857 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143857 915__ $$0StatID:(DE-HGF)9930$$2StatID$$aIF >= 30$$bLANCET ONCOL : 2017
000143857 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000143857 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lNachwuchsgruppe Pädiatrische Gliomforschung$$x1
000143857 980__ $$ajournal
000143857 980__ $$aVDB
000143857 980__ $$aI:(DE-He78)B062-20160331
000143857 980__ $$aI:(DE-He78)B360-20160331
000143857 980__ $$aUNRESTRICTED